Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 11, 2025

Live coverage: Federal Reserve cuts interest rates by 0.25%, Powell warns there's 'no risk-free path'

View original at finance.yahoo.com
Live coverage: Federal Reserve cuts interest rates by 0.25%, Powell warns there's 'no risk-free path' The Federal Reserve cut interest rates by 25 basis points at the conclusion of its two-day meeting on Wednesday, marking the central bank's third cut of the year…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • US interest rates should be much lower and are currently 3 percentage points too high

    80% confidence
  • The balance of risks has shifted toward the labor market after downside risks to employment rose in recent months

    80% confidence
  • There is no risk-free path for policy as the Fed navigates tension between employment and inflation goals

    80% confidence
  • Three factors will help the economy in 2026: resilient consumer spending, AI spending on data centers, and supportive fiscal policy

    80% confidence
  • The Fed's 0.25% rate cut is too small and should have been doubled, at least doubled

    80% confidence
  • Housing is going to be a problem because the Fed doesn't have tools to address structural housing shortage

    80% confidence
  • There is no need for another rate cut from the Federal Reserve

    80% confidence
  • There are inflationary forces from governments borrowing record amounts, immigration reform fractionalizing labor supply, and tariffs fractionalizing goods flow

    80% confidence
  • The Fed doesn't expect its next move to be a rate hike

    80% confidence
  • The Fed will cast a skeptical eye on shutdown-distorted economic data, particularly household survey data and CPI

    80% confidence
  • Tariffs are causing most of the inflation overshoot

    80% confidence
  • The Fed will not cut rates again until after a new Chair replaces Jerome Powell in May

    80% confidence
  • Powell sounded very upbeat on productivity and growth, including AI effects

    80% confidence
  • A 25 basis point decline in the federal funds rate won't make much difference for housing affordability

    80% confidence
  • The effects of tariffs on inflation will be relatively short-lived, effectively a one-time shift in the price level

    80% confidence
  • The baseline outlook is for solid growth next year

    80% confidence
  • A quarter-point change in the federal funds rate is not going to make much of a difference in the housing market

    80% confidence
  • The Fed is killing growth because they're so afraid of inflation

    80% confidence
  • Assuming no major new tariff announcements, inflation from goods should peak in the first quarter of 2026

    80% confidence
  • AI job displacement is probably part of the story but not a big part yet

    80% confidence
  • There's actually not much the Fed can do about affordability issues

    80% confidence
  • The Fed's take on productivity and growth is very risk-friendly, with productivity possibly running about 2%

    80% confidence
  • If the Fed lowers interest rates, that's probably going to increase home prices even more

    80% confidence
  • The Fed expects tariffs to represent a one-time increase in prices and is focused on ensuring it stays that way

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com